CD6 is a therapeutic target for LN
CD6 is a therapeutic target for LN
About this item
Full title
CD6 is a therapeutic target for LN
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Nature reviews. Rheumatology, 2022-03, Vol.18 (3), p.125-125
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
New research identifies the CD6 ligand ALCAM as a urinary biomarker of lupus nephritis, and shows that CD6 blockade can reduce lupus nephritis disease activity.
Alternative Titles
Full title
CD6 is a therapeutic target for LN
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2627135407
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2627135407
Other Identifiers
ISSN
1759-4790
E-ISSN
1759-4804
DOI
10.1038/s41584-022-00756-w
